Gilead Announces 11-Year Plan to Donate PrEP Medication to 200,000 Per Year

May 09, 2019 | Kim Rodgers

On May 9, 2019, Health and Human Services Secretary Alex M. Azar II announced that, as a result of discussions between the Trump Administration and Gilead Sciences, Inc., the pharmaceutical company has agreed to donate pre-exposure prophylaxis (PrEP) medication for up to 200,000 individuals each year for up to 11 years. PrEP is used to reduce the risk of HIV infection in individuals who are at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.

The agreement between the U.S. Department of Health and Human Services and Gilead will last until at least December 31, 2025 and possibly through December 31, 2030, and will provide medication to treat individuals who are at risk for HIV and who are uninsured. This donation will deliver Gilead’s PrEP medication Truvada, which currently carries a list price of more than $20,000 per patient per year, to up to 200,000 people per year, including in the states and counties identified as priority areas in the Trump Administration plan to end the HIV epidemic in America.

Gilead will donate Truvada until its second-generation HIV preventative medication, Descovy, becomes available. At that time, Gilead will donate Descovy. The agreement would end after 11 years, or when a generic version of Descovy becomes commercially available, whichever comes first. The government has agreed to cover costs associated with distributing the drugs.

Secretary Azar issued the following statement regarding the finalized agreement:

“Securing this commitment is a major step in the Trump Administration’s efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030. Under President Trump’s leadership, HHS worked with Gilead to secure preventative medication for individuals who might otherwise not be able to access or afford this important treatment. The majority of Americans who are at risk and who could protect themselves with PrEP are still not receiving the medication. This agreement will help close that gap substantially and deliver on President Trump’s promise to end the HIV epidemic in America.”

Additional Background:

In his State of the Union Address on February 5, 2019, President Donald J. Trump announced his Administration’s goal to end the HIV epidemic in the United States within 10 years. To achieve this goal and address the ongoing public health crisis of HIV, the initiative Ending the HIV Epidemic: A Plan for America will leverage the powerful data and tools now available to reduce new HIV infections in the United States by 75 percent in five years and by 90 percent by 2030. In his FY 2020 Budget, President Trump proposed historic new funding dedicated specifically to this initiative.

To read the HHS’s statement on FY2020 Budget proposal for ending the HIV epidemic In America, please visit: https://www.hhs.gov/about/news/2019/03/11/statement-on-fy2020-budget-proposal-for-ending-the-hiv-epidemic-in-america.html

For more information, please visit:www.hiv.gov


About Kim Rodgers

Pronouns: She/Her

Kim Rodgers was formerly the Communications Manager at NACCHO.

More posts by Kim Rodgers

Related Posts

I Stock 1182682774
  • Adverse Childhood Experiences (ACEs)
  • Behavioral Health
  • Community Health
  • Injury and Violence Prevention

Seeking LHD Participants for an Intersectional Data...

With support from the Centers for Disease Control and Prevention, NACCHO is...

Mar 28, 2024 | Camille Adams

Seeking LHD Participants for an Intersectional Data...

World TB Day 2024 1
  • ID Featured
  • Infectious Disease
  • Tuberculosis

Recognizing World TB Day 2024: The Role of Local Health...

LHDs across the nation actively work to eliminate TB through surveillance, case...

Mar 21, 2024 | Kimberly Nalley

Recognizing World TB Day 2024: The Role of Local Health...

I Stock 1318852282
  • COVID-19
  • Immunization
  • Infectious Disease
  • Influenza

Maternal and Child Vaccine Safety - Enhancing Vaccine...

After conducting a Rapid Community Assessment (RCA), in collaboration with the...

Mar 19, 2024 | Victoria Thompson, Clarissa Montes

Maternal and Child Vaccine Safety - Enhancing Vaccine...

Measles Blog 1
  • Tools & Resources
  • Community Health
  • ID Featured
  • Immunization

The Current Status of Measles in the US + Resources to...

This resource round-up aims to help local health departments and healthcare...

Mar 18, 2024 | Irene Halferty, Emma James, Victoria Thompson, Amy Maxson, Robin Mowson

The Current Status of Measles in the US + Resources to...

1

Building Community Resilience Through Maternal and Child...

NACCHO, with funding from the Centers for Disease Control and Prevention’s...

Mar 15, 2024 | Elana Filipos

Building Community Resilience Through Maternal and Child...

  • HIV, STI, & Viral Hepatitis

CDC Study Reveals Increase in Overdoses Associated with...

A recent CDC study demonstrates a need for LHDs and other local harm reduction...

Mar 14, 2024 | Kat Kelley, Anjana Rao, Grace Murtha

CDC Study Reveals Increase in Overdoses Associated with...

1

Bridging Maternal-Child Health (MCH), Infectious Disease...

Funded through the Center for Disease Control and Prevention’s (CDC) National...

Mar 12, 2024 | Elana Filipos

Bridging Maternal-Child Health (MCH), Infectious Disease...

Thumbnail youtube
  • Tools & Resources
  • Adverse Childhood Experiences (ACEs)

NACCHO Releases “Community Partnerships to Prevent...

The National Association of County and City Health Officials is pleased to...

Mar 12, 2024 | Camille Adams

NACCHO Releases “Community Partnerships to Prevent...

1
  • Maternal, Child, & Adolescent Health

NACCHO Provides Funding to Local Health Departments to...

The Maternal, Child, and Adolescent Health team has selected 14 new local...

Mar 11, 2024 | Ryanna Quazi

NACCHO Provides Funding to Local Health Departments to...

Back to Top